Comparison of Synovial Fluid Cytokine Levels between Traumatic Knee Injury and End-Stage Osteoarthritis

Abstract

Degenerative osteoarthritis (OA) has been associated with elevated synovial fluid cytokines. It is unclear whether traumatic knee injuries are a trigger to the chemical process that leads to OA. The purpose of this study was to compare the synovial fluid cytokine levels between knees undergoing arthroscopy due to a documented inciting injury and knees undergoing primary arthroplasty due to end-stage OA without a previous inciting injury. Synovial fluid samples were prospectively collected from knees undergoing arthroscopic surgeries due to ligamentous or meniscal knee injuries (knee injury group, n = 16) and primary arthroplasty due to OA (end-stage OA group, n = 14). In the knee injury group, patients had none or minimal OA and at least 30 days from the inciting injury. Exclusion criteria for both groups included inflammatory arthropathy (n = 1) and insufficient fluid for analysis (n = 1). In addition to synovial fluid cytokines, preoperative demographic, clinical, and functional data (Knee Injury and Osteoarthritis Outcome Score [KOOS]) were collected and compared between the groups. The end-stage OA group had higher age (p < 0.0001), body mass index (p = 0.0061), Charlson comorbidity index (<0.0001), and OA classification (p < 0.0001). Preoperative KOOS were similar between the groups. Interleukin-6 (IL-6) and IL-8 were elevated in the end-stage OA group compared with the knee injury group (p = 0.04 and 0.006, respectively). Granulocyte-macrophage colony-stimulating factor, interferon gamma, IL-1β, IL-12p70, IL-2, IL-10, and tumor necrosis factor alpha were not statistically different between the groups. A similar synovial fluid cytokine profile was found between the two groups. The elevation of IL-6 and IL-8 in the end-stage OA group indicates the potential role that these proinflammatory cytokines may have in long-term cartilage damage.

Keywords

osteoarthritis - synovial fluid - cytokines - knee - interleukin

• References

• 1 Lohmander LS, Englund PM, Dahl LL, Roos EM. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med 2007; 35 (10) 1756-1769
• 2 Øiestad BE, Engebretsen L, Storheim K, Risberg MA. Knee osteoarthritis after anterior cruciate ligament injury: a systematic review. Am J Sports Med 2009; 37 (7) 1434-1443
• 3 Hunter DJ, Zhang YQ, Niu JB , et al. The association of meniscal pathologic changes with cartilage loss in symptomatic knee osteoarthritis. Arthritis Rheum 2006; 54 (3) 795-801
• 4 Roos EM. Joint injury causes knee osteoarthritis in young adults. Curr Opin Rheumatol 2005; 17 (2) 195-200
• 5 Bhattacharyya T, Gale D, Dewire P , et al. The clinical importance of meniscal tears demonstrated by magnetic resonance imaging in osteoarthritis of the knee. J Bone Joint Surg Am 2003; 85-A (1) 4-9
• 6 Ferretti A, Conteduca F, De Carli A, Fontana M, Mariani PP. Osteoarthritis of the knee after ACL reconstruction. Int Orthop 1991; 15 (4) 367-371
• 7 Englund M, Lohmander LS. Risk factors for symptomatic knee osteoarthritis fifteen to twenty-two years after meniscectomy. Arthritis Rheum 2004; 50 (9) 2811-2819
• 8 Sandell LJ, Aigner T. Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res 2001; 3 (2) 107-113
• 9 Haseeb A, Haqqi TM. Immunopathogenesis of osteoarthritis. Clin Immunol 2013; 146 (3) 185-196
• 10 Irie K, Uchiyama E, Iwaso H. Intraarticular inflammatory cytokines in acute anterior cruciate ligament injured knee. Knee 2003; 10 (1) 93-96
• 11 Bigoni M, Sacerdote P, Turati M , et al. Acute and late changes in intraarticular cytokine levels following anterior cruciate ligament injury. J Orthop Res 2013; 31 (2) 315-321
• 12 Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16 (4) 494-502
• 13 Dabitao D, Margolick JB, Lopez J, Bream JH. Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytometric Bead Array. J Immunol Methods 2011; 372 (1–2): 71-77
• 14 Cuellar VG, Cuellar JM, Golish SR, Yeomans DC, Scuderi GJ. Cytokine profiling in acute anterior cruciate ligament injury. Arthroscopy 2010; 26 (10) 1296-1301
• 15 Ajuied A, Wong F, Smith C , et al. Anterior cruciate ligament injury and radiologic progression of knee osteoarthritis: a systematic review and meta-analysis. Am J Sports Med 2014; 42 (9) 2242-2252
• 16 Roos H, Laurén M, Adalberth T, Roos EM, Jonsson K, Lohmander LS. Knee osteoarthritis after meniscectomy: prevalence of radiographic changes after twenty-one years, compared with matched controls. Arthritis Rheum 1998; 41 (4) 687-693
• 17 Brown TD, Johnston RC, Saltzman CL, Marsh JL, Buckwalter JA. Posttraumatic osteoarthritis: a first estimate of incidence, prevalence, and burden of disease. J Orthop Trauma 2006; 20 (10) 739-744
• 18 Campbell IK, Piccoli DS, Roberts MJ, Muirden KD, Hamilton JA. Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum 1990; 33 (4) 542-552
• 19 Marks PH, Donaldson MLC. Inflammatory cytokine profiles associated with chondral damage in the anterior cruciate ligament-deficient knee. Arthroscopy 2005; 21 (11) 1342-1347
• 20 Kaneko S, Satoh T, Chiba J, Ju C, Inoue K, Kagawa J. Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther 2000; 6 (2) 71-79
• 21 Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002; 39 (1–2): 237-246
• 22 Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest 1989; 83 (2) 585-592
• 23 Nietfeld JJ, Wilbrink B, Helle M , et al. Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum 1990; 33 (11) 1695-1701
• 24 Cawston TE, Curry VA, Summers CA , et al. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum 1998; 41 (10) 1760-1771
• 25 Rowan AD, Koshy PJ, Shingleton WD , et al. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum 2001; 44 (7) 1620-1632
• 26 D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178 (3) 1041-1048
• 27 Yu CL, Sun KH, Shei SC , et al. Interleukin 8 modulates interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha release from normal human mononuclear cells. Immunopharmacology 1994; 27 (3) 207-214
• 28 Hirota K, Akahoshi T, Endo H, Kondo H, Kashiwazaki S. Production of interleukin 8 by cultured synovial cells in response to interleukin 1 and tumor necrosis factor. Rheumatol Int 1992; 12 (1) 13-16
• 29 Kristensen MS, Paludan K, Larsen CG , et al. Quantitative determination of IL-1 alpha-induced IL-8 mRNA levels in cultured human keratinocytes, dermal fibroblasts, endothelial cells, and monocytes. J Invest Dermatol 1991; 97 (3) 506-510
• 30 Van Damme J, Bunning RA, Conings R, Graham R, Russell G, Opdenakker G. Characterization of granulocyte chemotactic activity from human cytokine-stimulated chondrocytes as interleukin 8. Cytokine 1990; 2 (2) 106-111
• 31 Struglics A, Larsson S, Kumahashi N, Frobell R, Lohmander LS. Changes in cytokines and aggrecan ARGS neoepitope in synovial fluid and serum and in C-terminal crosslinking telopeptide of type II collagen and N-terminal crosslinking telopeptide of type I collagen in urine over five years after anterior cruciate ligament rupture: an exploratory analysis in the knee anterior cruciate ligament, nonsurgical versus surgical treatment trial. Arthritis Rheum (Munch) 2015; 67 (7) 1816-1825
• 32 Cameron M, Buchgraber A, Passler H , et al. The natural history of the anterior cruciate ligament-deficient knee. Changes in synovial fluid cytokine and keratan sulfate concentrations. Am J Sports Med 1997; 25 (6) 751-754
• 33 Morisugi T, Tanaka Y, Kawakami T, Kirita T. Mechanical stretch enhances NF-kappaB-dependent gene expression and poly(ADP-ribose) synthesis in synovial cells. J Biochem 2010; 147 (5) 633-644
• 34 Yang KG, Saris DB, Verbout AJ, Creemers LB, Dhert WJ. The effect of synovial fluid from injured knee joints on in vitro chondrogenesis. Tissue Eng 2006; 12 (10) 2957-2964
• 35 Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011; 7 (1) 33-42
• 36 Genovese MC, McKay JD, Nasonov EL , et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58 (10) 2968-2980
• 37 Smolen JS, Beaulieu A, Rubbert-Roth A , et al; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371 (9617): 987-997
• 38 Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010; 62 (1) 33-43
• 39 Yang XD, Corvalan JR, Wang P, Roy CM, Davis CG. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 1999; 66 (3) 401-410
• 40 Broaddus VC, Boylan AM, Hoeffel JM , et al. Neutralization of IL-8 inhibits neutrophil influx in a rabbit model of endotoxin-induced pleurisy. J Immunol 1994; 152 (6) 2960-2967